<DOC>
	<DOCNO>NCT01464411</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness Dasatinib first line therapy patient newly diagnose chronic myeloid leukemia chronic phase Japan .</brief_summary>
	<brief_title>Dasatinib Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Japan</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Newly diagnose Chronic Myeloid Leukemia Chronic Phase 20 year old ECOG performance status ( PS ) score 02 Adequate organ function ( hepatic , renal lung ) Signed write informed consent A case double cancer activity Women pregnant breastfeed The case Pleural effusion clearly Patients complication history severe uncontrolled cardiovascular failure follow Myocardial infarction whithin 6 month Angina within 3 month Congestive heart failure within 3 month QTc interval 450msec baseline A serious uncontrolled medical disorder would impair ability subject receive protocol therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>chronic phase</keyword>
	<keyword>Phase II</keyword>
	<keyword>dasatinib</keyword>
</DOC>